Nisa Investment Advisors LLC Sells 4,201 Shares of Insulet Corporation $PODD

Nisa Investment Advisors LLC reduced its holdings in Insulet Corporation (NASDAQ:PODD) by 48.9% during the third quarter, Holdings Channel.com reports. The fund owned 4,388 shares of the medical instruments supplier’s stock after selling 4,201 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Insulet were worth $1,355,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of PODD. Curi Capital LLC grew its holdings in shares of Insulet by 0.8% during the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after purchasing an additional 36 shares in the last quarter. Evelyn Partners Investment Management Services Ltd lifted its position in Insulet by 28.7% during the second quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier’s stock valued at $55,000 after purchasing an additional 39 shares during the last quarter. PDS Planning Inc grew its stake in Insulet by 5.1% in the 3rd quarter. PDS Planning Inc now owns 821 shares of the medical instruments supplier’s stock worth $253,000 after buying an additional 40 shares in the last quarter. Camarda Financial Advisors LLC increased its holdings in shares of Insulet by 0.5% in the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock worth $2,304,000 after buying an additional 40 shares during the last quarter. Finally, Sequoia Financial Advisors LLC increased its holdings in shares of Insulet by 2.3% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 2,017 shares of the medical instruments supplier’s stock worth $634,000 after buying an additional 45 shares during the last quarter.

Insulet Stock Up 1.7%

PODD opened at $282.89 on Thursday. Insulet Corporation has a 12 month low of $230.05 and a 12 month high of $354.88. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.68. The business’s 50-day moving average price is $304.67 and its 200-day moving average price is $311.18. The company has a market cap of $19.90 billion, a P/E ratio of 82.00, a P/E/G ratio of 1.55 and a beta of 1.40.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.11. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The company had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. During the same period in the prior year, the business posted $1.08 EPS. Insulet’s quarterly revenue was up 29.9% compared to the same quarter last year. On average, equities analysts expect that Insulet Corporation will post 3.92 EPS for the current year.

Analysts Set New Price Targets

PODD has been the subject of a number of research analyst reports. Raymond James Financial lifted their price objective on shares of Insulet from $366.00 to $385.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a research report on Wednesday, October 8th. Wolfe Research lifted their price target on Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Stifel Nicolaus began coverage on Insulet in a research report on Tuesday, October 21st. They set a “buy” rating and a $370.00 price objective on the stock. Finally, UBS Group restated a “buy” rating on shares of Insulet in a research report on Thursday, December 18th. Twenty-one research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and an average price target of $379.10.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.